Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product launches and Phase 3 trial results that may lead to higher earnings estimates. The analyst a ...

Core Insights - Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are significant players in the pharmaceutical industry with diverse product portfolios [1][2] - Merck is recognized for its leadership in oncology, while Bristol Myers focuses on breakthrough therapies across multiple therapeutic areas [1][2] Merck (MRK) Overview - Merck has over six blockbuster drugs, with Keytruda accounting for 54% of total sales in 2025, driving revenue growth [3][4] - Keytruda's sales increased by approximately 7% in 2025, benefiting from its approval for various oncology indications [4] - The FDA approved Keytruda Qlex for subcutaneous administration in September 2025, with peak sales targeted at $35 billion by 2028 [5] - Other oncology drugs like Welireg, Lynparza, and Lenvima are contributing to growth, alongside a strong launch of Winrevair in pulmonary arterial hypertension [6] - Merck is enhancing its vaccine portfolio, particularly with the new 21-valent pneumococcal conjugate vaccine, Capvaxive [7] - The company has around 80 ongoing late-stage studies, expecting over $70 billion in potential commercial opportunities by the mid-2030s [8] Bristol Myers Squibb (BMY) Overview - BMY's growth portfolio includes key brands such as Opdivo, Yervoy, and Reblozyl, with a strong oncology focus [12] - Opdivo's consistent label expansion has maintained its momentum, and the approval of Opdivo Qvantig has strengthened its franchise [13] - BMY's Reblozyl sales exceed $2 billion annually, and strong performance in cardiovascular drug Camzyos has boosted revenues [14] - However, legacy drugs face significant generic competition, with expected sales declines of 12-16% in 2026 [15] - BMY is pursuing strategic acquisitions and collaborations, including a recent agreement with BioNTech to co-develop a bispecific antibody [16][17] - The company aims for $2 billion in annualized cost savings by the end of 2027, having achieved approximately $1 billion in savings in 2025 [18] Financial Performance and Valuation - MRK's 2026 sales are estimated to increase by 2.59%, but EPS is expected to decline by 38.75% [20] - BMY's 2026 sales are projected to decrease by 2.32%, while EPS is expected to increase by 0.33% [20] - MRK shares trade at 21X forward earnings, while BMY trades at 9.74X, with the industry average at 18.74X [24] - BMY offers a higher dividend yield of 4.22% compared to MRK's 2.79% [25] Investment Outlook - BMY is currently viewed as a stronger near-term investment option compared to MRK, which faces multiple headwinds [9][30] - BMY's strategic initiatives and new drug approvals position it favorably against MRK's challenges, including declining sales of Gardasil and competitive pressures on Keytruda [27][30]

Group 1: Financial Performance - Merck expects sales for 2026 to be between $65.5 billion and $67 billion, with adjusted earnings per share projected at $5.00 to $5.15, which is below Wall Street expectations due to one-time costs from the acquisition of Cidara Therapeutics [2] Group 2: Company Status - Keytruda's key patent is expected to gradually expire starting in 2028, with its growth showing signs of slowing down, as evidenced by 2025 sales of $31.7 billion, reflecting a 7% year-over-year increase [3] - Merck is in talks to acquire biotechnology company Revolution Medicines for a potential price of $28 billion to $32 billion, aiming to enhance its oncology pipeline with the experimental drug Daraxonrasib [4] - Sales of the HPV vaccine Gardasil declined by 39% year-over-year to $5.233 billion in 2025, impacted by decreased demand in China and updated vaccination guidelines in the U.S., necessitating ongoing monitoring of its recovery [6] Group 3: Product Development Progress - The pulmonary arterial hypertension drug Winrevair (sotatercept) achieved sales of $1.443 billion in 2025 and is expected to gain FDA approval for new indications in 2026, positioning it as a key product [5] - Oral PCSK9 inhibitor Enlicitide and other cardiovascular products are in late-stage development and may represent new growth opportunities [5]

Core Insights - Merck (MRK.US) is actively pursuing acquisitions, product innovation, and new drug pipelines, which may significantly impact its future strategy and performance [1] Recent Events - Merck is in talks to acquire cancer drug developer Revolution Medicines for an estimated $28 billion to $32 billion, which would introduce the experimental drug Daraxonrasib targeting RAS gene mutation cancers, marking one of the largest deals in the pharmaceutical industry since Pfizer's acquisition of Seagen at the end of 2023 [2] - The company has also completed the acquisition of Cidara Therapeutics to strengthen its product pipeline [2] Business Progress - The subcutaneous formulation of Keytruda (Qlex) has been submitted for approval in the U.S., EU, and China, addressing challenges from the intravenous version's key patent expiration in 2028. Wolfe Research estimates that by 2029, approximately 41% of Keytruda's intravenous revenue may transition to the subcutaneous version [3] - New indications for Keytruda, including combination therapy with Moderna's mRNA vaccine and perioperative treatment for bladder cancer, are in progress [3] Performance Overview - The pulmonary arterial hypertension drug Winrevair (sotatercept) is projected to achieve sales of $1.443 billion by 2025 and is expected to receive FDA approval for new indications in 2026 [4] - The oral PCSK9 inhibitor Enlicitide has successfully completed Phase III clinical trials, potentially offering new options for cardiovascular disease patients [4] - The animal health business is expected to generate $6.4 billion in sales by 2025, reflecting an 8% year-over-year growth, while the diabetes drug sitagliptin is projected to generate $2.544 billion in revenue [4] Company Status - Merck's 2025 financial report anticipates 2026 sales between $65.5 billion and $67 billion, with adjusted EPS ranging from $5 to $5.15, which is below market expectations [5] - The company faces challenges including a decline in sales of the HPV vaccine Gardasil (projected at $5.2 billion for 2025, down 39% year-over-year), a slow recovery in the Chinese market, and a 12% decrease in R&D investment [5] Institutional Views - In January 2026, Wolfe Research upgraded Merck's rating to "Outperform" with a target price of $135, citing the company's position in a catalyst-rich phase through acquisitions and product innovation [6] - As of February 2, 2026, Merck's stock was priced at $113.37, reflecting a 14.72% increase over the past 52 weeks [6]

Core Viewpoint - Bernstein maintains a "Market Perform" rating for Merck, adjusting the price target from $95 to $100, indicating cautious optimism about the company's future performance [1][6] Financial Performance - Merck's fourth-quarter 2025 results show adjusted earnings per share (EPS) of $2.04, slightly above the Zacks Consensus Estimate of $2.03, representing a 19% increase year-over-year [2] - The company's revenues for the quarter reached $16.4 billion, reflecting a 5% year-over-year growth and surpassing the Zacks Consensus Estimate of $16.19 billion [2] Key Product Contribution - Keytruda, Merck's flagship product, generated $8.37 billion in sales during the quarter, marking a 5% increase [3] 2026 Outlook - Merck's 2026 revenue projection is between $65.5 billion and $67 billion, below analysts' estimates of $67.6 billion [4] - The company expects adjusted EPS between $5 and $5.15, compared to the anticipated $5.36, which includes a $9 billion one-time charge related to the acquisition of Cidara Therapeutics [4] Strategic Response - To address challenges, Merck plans to reduce costs by $3 billion by 2027 and continue investing in its pipeline and acquisitions, aiming to mitigate the effects of future patent expirations [5] - Despite challenges, Merck's market capitalization remains robust at approximately $289.39 billion, with a trading volume of 25.57 million shares [5]

Core Viewpoint - Merck & Co., Inc. reported fourth-quarter results that met earnings expectations and slightly exceeded revenue forecasts, leading to a more than 2% increase in share price intraday [1] Group 1: Financial Performance - The company posted adjusted earnings per share of $2.04, aligning with analyst estimates [1] - Revenue increased by 5% year over year to $16.4 billion, surpassing the consensus estimate of $16.18 billion [1] Group 2: Growth Drivers - Growth was primarily driven by strong performance in oncology and animal health, along with contributions from newer products [2] - KEYTRUDA sales rose by 7% to $8.37 billion during the quarter [2] - Animal health revenue increased by 8% to $1.51 billion, supported by robust livestock demand [2] Group 3: Future Outlook - The 2026 outlook disappointed investors, with earnings forecasted at $5.00 to $5.15 per share, below analyst expectations of $5.63 [3] - A one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics impacted the earnings forecast [3] - Revenue for 2026 is projected at $65.5 billion to $67.0 billion, slightly below the consensus of $67.58 billion [3] Group 4: Full-Year Sales - For the full year 2025, Merck reported worldwide sales of $65.0 billion, representing 1% growth, or 2% growth excluding foreign exchange [4] - KEYTRUDA generated $31.7 billion in annual sales [4] - Newer products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million, respectively [4]

Core Insights - Merck's financial performance for 2025 shows steady growth driven by Keytruda, new products like Winrevair and Capvaxive, and stable animal health business, with total sales reaching $65 billion, a 1% year-over-year increase [1] - The company projects 2026 sales between $65.5 billion and $67 billion, with adjusted EPS expected to be between $5.00 and $5.15, both below Wall Street expectations [1][6] - A significant one-time expense from the acquisition of Cidara Therapeutics is expected to impact 2026 adjusted EPS, which includes approximately $3.65 per share related to this acquisition [1][6] Financial Performance - For Q4 2025, sales were $16.4 billion, a 4% increase from Q4 2024, while total sales for the year were $65.011 billion, up 1% [2] - Non-GAAP EPS for 2025 was $8.98, reflecting a 17% increase year-over-year, while GAAP EPS was $7.28, an 8% increase [2] Product Performance - Gardasil sales faced significant challenges, with Q4 sales at $1.031 billion, a 35% decline year-over-year, and annual sales down 39% to $5.233 billion [3] - Keytruda sales reached $8.4 billion in Q4, a 7% increase, with annual sales surpassing $30 billion for the first time, totaling $31.68 billion [4] - New products like Winrevair and Capvaxive showed strong performance, with Winrevair achieving $1.443 billion in annual sales, and Capvaxive reaching $759 million [5] Strategic Outlook - Merck is focusing on product portfolio transformation to mitigate the impact of patent expirations and competition, with strategic acquisitions being a key part of this strategy [5] - The company has identified potential acquisition opportunities valued in the billions to drive future growth [4] 2026 Guidance - The 2026 guidance includes significant one-time costs from the Cidara acquisition, with adjusted EPS expected to be impacted by these costs [6][7] - The company anticipates a gross margin of approximately 82% for 2026, with adjusted operating expenses projected between $35.9 billion and $36.9 billion [7]

Financial Data and Key Metrics Changes - Total company revenues for Q4 2025 were $16.4 billion, reflecting a 5% increase, or 4% excluding foreign exchange impact [14] - Earnings per share (EPS) were reported at $2.04, with guidance for 2026 EPS expected to be between $5.00 and $5.15 [21][22] - Gross margin decreased to 79.7%, down 1.1 percentage points due to higher inventory reserves [19] Business Line Data and Key Metrics Changes - Oncology sales, particularly from the Keytruda family, increased by 5% to $8.4 billion, driven by strong demand in earlier-stage cancers [15] - Sales of Welireg grew 37% to $220 million, primarily due to increased use in advanced renal cell carcinoma [16] - Vaccines sales, specifically Gardasil, decreased by 35% to $1 billion, attributed to lower demand in China and Japan [16] - The animal health business saw a 6% increase in sales, with livestock sales growing by 9% [19] Market Data and Key Metrics Changes - In the U.S., Keytruda's growth was negatively impacted by approximately $200 million due to the timing of purchases [15] - Sales of Capvaxive in pneumococcal vaccines reached $279 million, driven by increased seasonal immunization activity [17] - Winrevair's global sales were $467 million, reflecting strong demand for pulmonary arterial hypertension treatment [18] Company Strategy and Development Direction - The company aims to deliver transformative medicines and vaccines, with a focus on breakthrough science and innovation [6] - A significant commercial opportunity of over $70 billion is projected by the mid-2030s, bolstered by new product launches and pipeline expansion [7] - The company is committed to business development and strategic acquisitions, including Verona Pharma and Cidara Therapeutics, to enhance its portfolio [9][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustainable growth post-Keytruda LOE, emphasizing a robust pipeline and potential for new product launches [6][66] - The company anticipates challenges from generic competition and price setting but expects to achieve growth driven by new launches and strong performance in oncology and animal health [23][66] - Management highlighted the importance of maintaining a disciplined approach to capital allocation and investments in innovation [24] Other Important Information - The company completed the acquisition of Cidara Therapeutics, enhancing its infectious disease portfolio with MK-1406, a long-acting antiviral candidate [9][29] - The company is focused on executing multiple product launches and advancing its clinical pipeline, with significant milestones expected in 2026 [12][37] Q&A Session Summary Question: Can you elaborate on the CD388 asset and its potential? - Management acknowledged the importance of the flu season and emphasized the need for robust data across multiple populations for the ongoing trial [42][44] Question: Are there plans to explore sac-TMT in first-line settings? - Management expressed confidence in the sac-TMT program, highlighting its potential as a best-in-class ADC and the ambition to explore various tumor types [48] Question: How should we model the IP runway for Keytruda? - Management clarified the patent situation for Keytruda, indicating potential extensions beyond 2028 and strategies to drive adoption of QLEX [53][55] Question: Can you contextualize the importance of a dual regimen for HIV treatment? - Management highlighted the unique mechanism of Islatravir and the unmet need for dual regimens, emphasizing the potential benefits for patients [59] Question: What is the outlook for Merck's growth in the coming years? - Management expressed confidence in sustainable growth driven by a strong pipeline and significant commercial opportunities, countering the notion of modest growth [66]

Core Viewpoint - Merck anticipates a decline in earnings for 2026 due to the acquisition of Cidara Therapeutics [1] Group 1 - The acquisition of Cidara Therapeutics is expected to impact Merck's financial performance negatively in 2026 [1]

Core Insights - The sentiment among pharmaceutical companies attending the upcoming J.P. Morgan Healthcare Conference in San Francisco is significantly more relaxed compared to 2025, with previous uncertainties regarding drug pricing policies and tariffs largely dissipated [2][4] - The biopharmaceutical sector has seen a more than doubling of deal activity over the past year, with expectations for 2026 to surpass last year's performance [2][5] Group 1: Market Sentiment and Deal Activity - Pharmaceutical companies reached $130 billion in deals in 2025, a 124% increase from the previous year, with approximately 30 transactions exceeding $1 billion, marking a historical high [5] - The positive market reaction is attributed to an agreement with the White House aimed at lowering drug prices without significant adjustments to financial outlooks from related companies [4] Group 2: Acquisition Trends - Major pharmaceutical companies like Merck, Pfizer, and Bristol-Myers Squibb are under pressure to replenish their product pipelines as patents for blockbuster drugs are set to expire within the next five years, threatening over $300 billion in sales [8] - There has been a surge in public bidding wars for biotech firms developing potential blockbuster drugs, indicating a strong desire among CEOs to pursue acquisitions [9][10] Group 3: Investment Climate and IPO Outlook - The current high stock prices are encouraging CEOs to pursue mergers and acquisitions more aggressively, with a notable increase in competition for biotech companies [9] - Despite the optimistic outlook, rising valuations may deter potential buyers, leading to a cautious approach towards major acquisitions [11][12] - There is an expectation of a significant number of private biotech companies going public this year, with venture capital increasingly focusing on later-stage companies in anticipation of a more favorable IPO environment in 2026 [12]